IP Library Granted Patent US 8,721,990
Granted Patent B2
US 8,721,990 · App. 12/595,741 · Granted May 13, 2014

Assay device

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,721,990
App. No.
12/595,741
Granted
May 13, 2014
Kind
B2
Abstract

Disclosed is an assay device for the determination of the presence and/or extent if an analyte in a liquid sample over an extended concentration range comprising a first assay and a second assay, wherein the first assay for an analyte comprises a first flow-path having a sole detection zone capable of immobilizing a labelled binding reagent and the second assay for said analyte comprises a second flow-path having a sole detection zone capable of immobilizing a labelled binding reagent, wherein the presence of labelled binding reagent at the detection zones provides an indication of the presence and/or extent of analyte in said liquid sample.

Claims (32)

1. An assay device for the determination of hCG in a liquid sample over an extended concentration rang, comprising a first assay and a second assay,

wherein the first assay comprises a first flow-path having a sole first assay detection zone and a mobilisable, labeled, hCG-binding reagent provided upstream from the first assay detection zone; and the second assay comprises a second flow-path having a sole second assay detection zone, a mobilisable, labeled, hCG-binding reagent provided upstream from the second assay detection zone, and a mobilisable scavenger binding reagent for hCG provided upstream from the second assay detection zone;

wherein the first and second assay detection zones each independently comprise an immobilised reagent that is capable of immobilising the respective labeled, hCG-binding reagent in the presence of hCG;

wherein said first and second assays are provided on separate substrates, or on a common substrate but with the first and second flow-paths fluidically isolated from one another;

wherein the immobilisation of the labeled, hCG-binding reagents at the detection zones provides an indication of hCG in said liquid sample; and wherein the first assay provides an indication of hCG in a first concentration range and the second assay provides an indication of hCG in a second, higher concentration range.

2. The device according to claim 1 wherein the first and/or second flow-path comprises a porous carrier.

3. The device according to claim 2 wherein the porous carrier is a lateral flow porous carrier.

4. The device according to claim 1 wherein for the second assay, the scavenger binding reagent has a higher binding affinity for hCG than the mobilisable, labeled, hCG-binding reagent.

5. The device according to claim 1 wherein the mobilisable, labeled, hCG-binding reagent and the scavenger binding reagent of the second assay bind to respectively a first and second binding region of hCG, and the second assay detection zone comprises an immobilised binding reagent for a second binding region of hCG.

6. The device according to claim 1 wherein the mobilisable, labeled, binding reagent and the scavenger binding reagent of the second assay are provided in the same region.

7. The device according to claim 1 wherein the labelled binding reagent is labelled with an optically detectable particle.

8. The device according to claim 1 , comprising a common porous sample receiver.

9. The assay device according to claim 1 , wherein the first assay is a high sensitivity assay and the second assay is a low sensitivity hCG assay.

10. The device according to claim 1 , comprising a housing wherein the first and second assays are provided within said housing.

11. The device according to claim 1 for the detection of hCG analyte in urine wherein the device comprises:

a) an illumination and detection means for illuminating and detecting labelled binding optical reagent at the detection zones;

b) a computation means for calculating a level of hCG or a value corresponding to the level of hCG;

c) a display means for displaying a result of the assay test;

d) a stored base threshold value, wherein a level of hCG corresponding to a value below the stored base threshold is indicative of being not pregnant and wherein a level of hCG corresponding to a value at or above the stored base threshold is indicative of being pregnant;

e) two further first and second stored threshold values wherein a level of hCG corresponding to a value less than or equal to a first threshold value is indicative of a level of pregnancy in a first range, a level of hCG corresponding to a value greater than the second threshold is indicative of a level of pregnancy in a third range, and a level of hCG corresponding to a value greater or equal to the first threshold but less than the second threshold is indicative of a level of hCG in a second range, wherein the display means is capable of indicating either a not pregnant condition, or a pregnant condition and the extent of pregnancy.

12. The device according to claim 1 , wherein the scavenger binding reagent is unlabelled.

13. The device according to claim 1 , wherein the scavenger binding reagent of the second assay is capable of binding to the beta subunit of hCG, and the mobilisable, labeled, hCG-binding reagent of the second assay is capable of binding to the alpha subunit of hCG.

14. The device according to claim 1 , which is for the determination of the extent of pregnancy of a subject in time based units.

15. The device according to claim 14 , wherein the extent of pregnancy is determined in units of weeks.

16. The device according to claim 14 , wherein the determination of the extent of pregnancy is based upon stored reference values.

17. The device according to claim 1 , wherein said extended concentration range is the range of about 10 to about 250,000 mIU/ml hCG.

18. The device according to claim 1 , which does not contain more than two hCG assays.

19. The device according to claim 1 , wherein the immobilised reagents in the first and second assay detection zones are immobilised hCG-binding reagents.

20. The device according to claim 19 , wherein the immobilised reagents in the first and second assay detection zones are independently streptavidin or anti-biotin.

21. The device according to claim 1 , wherein the first and second concentration ranges overlap.

22. A method of determining the extent of pregnancy in a pregnant woman subject, the method comprising the step of analysing a urine sample from the subject using an assay device in accordance with claim 1 .

23. A method of determining pregnancy as well as the extent of pregnancy in a pregnant woman subject, the method comprising the step of analysing a urine sample from the subject using an assay device in accordance with claim 1 .

Assignments (3)
CONFIRMATORY ASSIGNMENT Recorded Oct 30, 2020
From: ALERE SWITZERLAND GMBH
To: ABBOTT RAPID DIAGNOSTICS INTERNATIONAL UNLIMITED COMPANY
Reel/Frame 054260/0479 →
CHANGE OF NAME Recorded Jul 8, 2010
From: INVERNESS MEDICAL SWITZERLAND GMBH
To: ALERE SWITZERLAND GMBH
Reel/Frame 024652/0378 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2010
From: RAJ, BALBIR; EAPEN, SAJI; LINLEY, EZRA
To: INVERNESS MEDICAL SWITZERLAND GMBH
Reel/Frame 024124/0613 →